# 18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.

> **NCT05983796** · NA · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 100 (estimated)

## Conditions studied

- 18F-HER2 PET

## Interventions

- **DIAGNOSTIC_TEST:** 18F-HER2 PET

## Key facts

- **NCT ID:** NCT05983796
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-10
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-09-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05983796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05983796, "18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05983796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*